BNTX Earnings Date: Nov 3, 2026 — BioNTech SE
NASDAQ · Healthcare · Biotechnology
Updated
When is BNTX's next earnings date?
BioNTech SE (BNTX) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026 at 6:45 AM ET (before market open). The consensus estimate is EPS of $0.85 on revenue of $1.17B.
How did BNTX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), BioNTech SE posted EPS of -$2.58 versus the -$2.40 estimate, a miss of 10.3%. Revenue was $122.8M against a $180.2M estimate. The stock's 1-day post-earnings move was -1.0%.
How much does BNTX stock move after earnings?
BNTX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -2.40 | -2.58 | -10.26% | $122.8M | ❌ Miss | -0.98% | +0.60% | +10.51% |
| 2026-05-05 | Q1 2026 | -2.52 | -2.28 | +9.52% | $138.0M | ✅ Beat | -3.88% | -6.05% | -10.97% |
| 2026-03-10 | Q4 2025 | -0.47 | -0.38 | +19.15% | $1.06B | ✅ Beat | -17.88% | -11.37% | -9.87% |
| 2025-11-03 | Q3 2025 | 0.75 | -0.14 | -118.67% | $1.78B | ❌ Miss | +0.04% | -0.74% | -7.51% |
| 2025-08-04 | Q2 2025 | -1.31 | -1.82 | -38.93% | $295.7M | ❌ Miss | +2.51% | +4.02% | -6.26% |
| 2025-05-05 | Q1 2025 | -2.35 | -1.82 | +22.55% | $192.2M | ✅ Beat | -3.66% | -11.60% | +10.20% |
| 2025-03-10 | Q4 2024 | 0.37 | 1.15 | +210.81% | $1.27B | ✅ Beat | -3.15% | -8.56% | -20.19% |
| 2024-11-04 | Q3 2024 | -1.67 | 0.89 | +153.29% | $1.37B | ✅ Beat | -2.25% | -0.75% | +3.69% |
Showing last 8 quarters.